NFE2 and cancer: Accumulating evidence has established the key ROS sensor NRF2 as a driver of cancer progression and metastasis, which also confers chemoresistance.[42, 43, 44] Using the N‐terminus of its basic leucine zipper domain, NRF2 can bind to the NF‐E2 site in the DNA‐globin gene cluster, which has been identified as an enhancer region encoding antioxidant proteins.[32, 45] Downregulation of NRF2 can significantly disrupt the global redox balance, resulting in uncontrolled ROS accumulation.